244 related articles for article (PubMed ID: 17391757)
1. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
Rohner A; Langenkamp U; Siegler U; Kalberer CP; Wodnar-Filipowicz A
Leuk Res; 2007 Oct; 31(10):1393-402. PubMed ID: 17391757
[TBL] [Abstract][Full Text] [Related]
2. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Lu X; Ohata K; Kondo Y; Espinoza JL; Qi Z; Nakao S
Cancer Sci; 2010 Mar; 101(3):609-15. PubMed ID: 20028385
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of NKG2D ligands by AML cells to increase sensitivity to NK cells: the tumour might strike back. Comment on "differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis" by Rohner et al. [Leuk Res 2007;31:1393-402].
Zimmer J; Michel T; Andrès E; Hentges F
Leuk Res; 2008 Apr; 32(4):676-7. PubMed ID: 17920678
[No Abstract] [Full Text] [Related]
7. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
[TBL] [Abstract][Full Text] [Related]
9. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
Bae DS; Hwang YK; Lee JK
Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
[TBL] [Abstract][Full Text] [Related]
10. NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells.
Chen XM; Xu XQ; Sun K; Hallett WH; Zhao JD; Zhang DL
Scand J Immunol; 2008 May; 67(5):441-7. PubMed ID: 18312485
[TBL] [Abstract][Full Text] [Related]
11. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
[TBL] [Abstract][Full Text] [Related]
12. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
14. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
15. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
Poggi A; Catellani S; Garuti A; Pierri I; Gobbi M; Zocchi MR
Leukemia; 2009 Apr; 23(4):641-8. PubMed ID: 19151770
[TBL] [Abstract][Full Text] [Related]
16. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
[TBL] [Abstract][Full Text] [Related]
17.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Bae JH; Kim SJ; Kim MJ; Oh SO; Chung JS; Kim SH; Kang CD
Cancer Sci; 2012 Jan; 103(1):7-16. PubMed ID: 21951556
[TBL] [Abstract][Full Text] [Related]
19. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.
Nanbakhsh A; Pochon C; Mallavialle A; Amsellem S; Bourhis JH; Chouaib S
Blood; 2014 Jun; 123(23):3585-95. PubMed ID: 24677544
[TBL] [Abstract][Full Text] [Related]
20. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
López-Soto A; Folgueras AR; Seto E; Gonzalez S
Oncogene; 2009 Jun; 28(25):2370-82. PubMed ID: 19430493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
